Loading
A phase 1/2 trial of Mezigdomide, Tazemetostat, Trametinib in multiple myeloma, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05372354 by Bristol-Myers Squibb, with 260 participants planned, started 2022-10-18 and due to reach its primary completion in 2026-10-12. Interventions recorded: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation).
Shares Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Multiple myeloma.